论文部分内容阅读
目的探讨慢性携带 HBV 孕妇妊娠晚期注射乙型肝炎免疫球蛋白(HBIG)对阻断母婴传播的效果。方法时10例慢性携带 HBV 未怀孕的育龄妇女和23例妊娠晚期妇女于注射3针HBIG 前后,应用定量 PCR(FQ-PCR)检测其血清 HBV DNA;对28例妊娠晚期注射3针 HBIG 母亲所生新生儿,应用 ELISA 检测血清抗-HBs。结果 10例慢性携带 HBV 育龄妇女和23例孕妇于注射3针 HBIG 前后血清 HBV DNA 水平分别为(8.18±0.50)lg 拷贝/ml 比(7.64±0.41)lg 拷贝/ml 和(6.83±1.51)lg 拷贝/ml 比(6.83±1.29)lg 拷贝/ml,差异无统计学意义(t=5.705,P>0.05和 t=0.048,P>0.05)。28例妊娠晚期注射3针 HBIG 母亲所生新生儿无一例抗-HBs 阳性。结论于孕晚期注射3针 HBIG 不能降低孕妇的血清 HBV DNA,也不能使新生儿获得抗-HBs,因此,用此法阻断HBV 母婴传播缺乏充分的科学依据。
Objective To investigate the effect of hepatitis B immunoglobulin (HBIG) injected in pregnant women with chronic HBV infection on the prevention of mother-to-child transmission. METHODS: Ten pregnant women of childbearing age and 23 women of pregnancy who had not been pregnant with HBV were enrolled in this study. Serum HBV DNA was detected by quantitative polymerase chain reaction (FQ-PCR) before and after 3-needle HBIG injection. Twenty-eight pregnant women Neonates, serum anti-HBs was detected by ELISA. Results The serum levels of HBV DNA in 10 women with HBV carriers and 23 pregnant women with chronic HBV infection were (8.18 ± 0.50) lg copies / ml (7.64 ± 0.41) lg copies / ml and (6.83 ± 1.51) lg (6.83 ± 1.29) lg copies / ml, the difference was not statistically significant (t = 5.705, P> 0.05 and t = 0.048, P> 0.05). None of the 28 newborn infants born to HBIG mothers injected with 3-pin pregnancy had a positive anti-HBs. Conclusions Injecting 3-needle HBIG in the third trimester of pregnancy can not reduce the serum HBV DNA of pregnant women, nor can it make neonatal get anti-HBs. Therefore, it is not sufficient scientific basis to block the mother-to-child transmission of HBV by this method.